4.4 Review

Treatment strategies for psoriatic arthritis

期刊

JOINT BONE SPINE
卷 85, 期 5, 页码 537-544

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.jbspin.2017.11.001

关键词

Psoriatic arthritis; Spondyloarthritis; Biologics

资金

  1. Abbvie
  2. Pfizer
  3. Roche-Chugai Bristol-Myers Squibb
  4. MSD
  5. UCB
  6. Novartis
  7. Janssen

向作者/读者索取更多资源

The therapeutic management of psoriatic arthritis has seen major changes over the last few years, as illustrated by the recent updates of the GRAPPA and EULAR recommendations. These changes were driven by new studies establishing important benefits from early management and tight control of disease activity. The concepts underlying the treatment of psoriatic arthritis must be reappraised in the light of these new data. The objectives of this review are to discuss new concepts, to describe and assess the new drug classes introduced for psoriatic arthritis and, whenever possible, to define the specific indications of each class based on the rheumatic disease phenotype and presence of extra articular manifestations. (C) 2017 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据